BioELife Corp (LITH)
0.00
USD |
OTCM |
May 03, 16:00
BioELife Max Drawdown (5Y): 100.0% for April 30, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
April 30, 2024 | 100.0% |
March 31, 2024 | 100.0% |
February 29, 2024 | 100.0% |
January 31, 2024 | 100.0% |
December 31, 2023 | 100.0% |
November 30, 2023 | 100.0% |
October 31, 2023 | 100.0% |
September 30, 2023 | 100.0% |
August 31, 2023 | 100.0% |
July 31, 2023 | 100.0% |
June 30, 2023 | 100.0% |
May 31, 2023 | 100.0% |
April 30, 2023 | 100.0% |
March 31, 2023 | 100.0% |
February 28, 2023 | 100.0% |
January 31, 2023 | 100.0% |
December 31, 2022 | 100.0% |
November 30, 2022 | 100.0% |
October 31, 2022 | 100.0% |
September 30, 2022 | 100.0% |
August 31, 2022 | 100.0% |
July 31, 2022 | 100.0% |
June 30, 2022 | 100.0% |
May 31, 2022 | 100.0% |
April 30, 2022 | 100.0% |
Date | Value |
---|---|
March 31, 2022 | 100.0% |
February 28, 2022 | 100.0% |
January 31, 2022 | 100.0% |
December 31, 2021 | 100.0% |
November 30, 2021 | 100.0% |
October 31, 2021 | 100.00% |
September 30, 2021 | 100.00% |
August 31, 2021 | 100.00% |
July 31, 2021 | 100.00% |
June 30, 2021 | 100.00% |
May 31, 2021 | 99.91% |
April 30, 2021 | 99.91% |
March 31, 2021 | 99.91% |
February 28, 2021 | 99.91% |
January 31, 2021 | 99.91% |
December 31, 2020 | 99.91% |
November 30, 2020 | 99.91% |
October 31, 2020 | 97.73% |
September 30, 2020 | 97.73% |
August 31, 2020 | 97.73% |
July 31, 2020 | 97.73% |
June 30, 2020 | 97.73% |
May 31, 2020 | 97.73% |
April 30, 2020 | 97.73% |
March 31, 2020 | 97.73% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
97.73%
Minimum
Jan 2020
100.0%
Maximum
Nov 2021
99.50%
Average
100.00%
Median
Max Drawdown (5Y) Benchmarks
NovaBay Pharmaceuticals Inc | 99.91% |
Palatin Technologies Inc | 96.46% |
iBio Inc | 99.97% |
Theriva Biologics Inc | 99.81% |
Oragenics Inc | 98.92% |